Cargando…

Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients

BACKGROUND: The consumption of carbapenems has increased worldwide, together with the increase in resistant gram negative bacilli. Subsequently, the prevalence of carbapenem-resistant Acinetobacter infections has increased rapidly and become a significant problem particularly in intensive care unit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogutlu, Aziz, Guclu, Ertugrul, Karabay, Oguz, Utku, Aylin Calica, Tuna, Nazan, Yahyaoglu, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898784/
https://www.ncbi.nlm.nih.gov/pubmed/24405720
http://dx.doi.org/10.1186/1476-0711-13-7
_version_ 1782300471458791424
author Ogutlu, Aziz
Guclu, Ertugrul
Karabay, Oguz
Utku, Aylin Calica
Tuna, Nazan
Yahyaoglu, Mehmet
author_facet Ogutlu, Aziz
Guclu, Ertugrul
Karabay, Oguz
Utku, Aylin Calica
Tuna, Nazan
Yahyaoglu, Mehmet
author_sort Ogutlu, Aziz
collection PubMed
description BACKGROUND: The consumption of carbapenems has increased worldwide, together with the increase in resistant gram negative bacilli. Subsequently, the prevalence of carbapenem-resistant Acinetobacter infections has increased rapidly and become a significant problem particularly in intensive care unit patients. The aim of the present study was to evaluate the changes in the prevalence of Acinetobacter infection by restricting the consumption of carbapenems in intensive care unit patients. METHODS: This study was conducted between May 1, 2011 and February 28, 2013. The amount of carbapenem consumption and the number of patients with multi-drug resistant Acinetobacter baumannii (MDRAB) isolates during the study period were retrospectively obtained from the records of the patients, who were hospitalized in the intensive care unit. The study period was divided into two periods named as: Carbapenem non-restricted period (CNRP) and carbapenem-restricted period (CRP). During CNRP, no restrictions were made on the use of carbapenems. During CRP, the use of carbapenems was not allowed if there was an alternative to carbapenems. Primary Endpoint: MDRAB infection after ICU admission. The definition of nosocomial infections related to Acinetobacter spp. was based on the criteria of the Center for Disease Control (CDC). The correlation between the amount of carbapenem consumption and the number of infections with MDRAB strains between the two periods were evaluated. RESULTS: During the study period, a total of 1822 patients’ (1053 patients in CNRP and 769 patients in CRP) records were evaluated retrospectively. A total of 10.82 defined daily dose (DDD/100 ICU days) of anti-pseudomonal carbapenem were used in CNRP, and this figure decreased to 6.95 DDD/100 ICU days in CRP. In the 8-month CNRP, 42 (3.98%) MDRAB-related nosocomial infections were detected, and 14 (1.82%) infections were detected in CRP (p = 0.012). CONCLUSION: The prevalence of MDRAB strains isolated in the CNRP was 2.24-fold higher than the prevalence in the CRP. The prevalence of Acinetobacter infections can be reduced by taking strict isolation measures as well as by implementing good antibiotics usage policy.
format Online
Article
Text
id pubmed-3898784
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38987842014-01-23 Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients Ogutlu, Aziz Guclu, Ertugrul Karabay, Oguz Utku, Aylin Calica Tuna, Nazan Yahyaoglu, Mehmet Ann Clin Microbiol Antimicrob Research BACKGROUND: The consumption of carbapenems has increased worldwide, together with the increase in resistant gram negative bacilli. Subsequently, the prevalence of carbapenem-resistant Acinetobacter infections has increased rapidly and become a significant problem particularly in intensive care unit patients. The aim of the present study was to evaluate the changes in the prevalence of Acinetobacter infection by restricting the consumption of carbapenems in intensive care unit patients. METHODS: This study was conducted between May 1, 2011 and February 28, 2013. The amount of carbapenem consumption and the number of patients with multi-drug resistant Acinetobacter baumannii (MDRAB) isolates during the study period were retrospectively obtained from the records of the patients, who were hospitalized in the intensive care unit. The study period was divided into two periods named as: Carbapenem non-restricted period (CNRP) and carbapenem-restricted period (CRP). During CNRP, no restrictions were made on the use of carbapenems. During CRP, the use of carbapenems was not allowed if there was an alternative to carbapenems. Primary Endpoint: MDRAB infection after ICU admission. The definition of nosocomial infections related to Acinetobacter spp. was based on the criteria of the Center for Disease Control (CDC). The correlation between the amount of carbapenem consumption and the number of infections with MDRAB strains between the two periods were evaluated. RESULTS: During the study period, a total of 1822 patients’ (1053 patients in CNRP and 769 patients in CRP) records were evaluated retrospectively. A total of 10.82 defined daily dose (DDD/100 ICU days) of anti-pseudomonal carbapenem were used in CNRP, and this figure decreased to 6.95 DDD/100 ICU days in CRP. In the 8-month CNRP, 42 (3.98%) MDRAB-related nosocomial infections were detected, and 14 (1.82%) infections were detected in CRP (p = 0.012). CONCLUSION: The prevalence of MDRAB strains isolated in the CNRP was 2.24-fold higher than the prevalence in the CRP. The prevalence of Acinetobacter infections can be reduced by taking strict isolation measures as well as by implementing good antibiotics usage policy. BioMed Central 2014-01-09 /pmc/articles/PMC3898784/ /pubmed/24405720 http://dx.doi.org/10.1186/1476-0711-13-7 Text en Copyright © 2014 Ogutlu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ogutlu, Aziz
Guclu, Ertugrul
Karabay, Oguz
Utku, Aylin Calica
Tuna, Nazan
Yahyaoglu, Mehmet
Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients
title Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients
title_full Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients
title_fullStr Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients
title_full_unstemmed Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients
title_short Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients
title_sort effects of carbapenem consumption on the prevalence of acinetobacter infection in intensive care unit patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898784/
https://www.ncbi.nlm.nih.gov/pubmed/24405720
http://dx.doi.org/10.1186/1476-0711-13-7
work_keys_str_mv AT ogutluaziz effectsofcarbapenemconsumptionontheprevalenceofacinetobacterinfectioninintensivecareunitpatients
AT gucluertugrul effectsofcarbapenemconsumptionontheprevalenceofacinetobacterinfectioninintensivecareunitpatients
AT karabayoguz effectsofcarbapenemconsumptionontheprevalenceofacinetobacterinfectioninintensivecareunitpatients
AT utkuaylincalica effectsofcarbapenemconsumptionontheprevalenceofacinetobacterinfectioninintensivecareunitpatients
AT tunanazan effectsofcarbapenemconsumptionontheprevalenceofacinetobacterinfectioninintensivecareunitpatients
AT yahyaoglumehmet effectsofcarbapenemconsumptionontheprevalenceofacinetobacterinfectioninintensivecareunitpatients